Delivery technologies for cancer immunotherapy

By Rachel S. Riley, C. June, Robert Langer, Michael J. Mitchell. Nature reviews. Drug discovery, 2019

2,125 citations recorded by the source corpus.

Immunotherapy has become a powerful clinical strategy for treating cancer. The number of immunotherapy drug approvals has been increasing, with numerous treatments in clinical and preclinical development. However, a key challenge in the broad implementation of immunotherapies for cancer remains the controlled modulation of the immune system, as these therapeutics have serious adverse effects including autoimmunity and nonspecific inflammation. Understanding how to increase the response rates to various classes of immunotherapy is key to improving efficacy and controlling these adverse effects. Advanced biomaterials and drug delivery systems, such as nanoparticles and the use of T cells to deliver therapies, could effectively harness immunotherapies and improve their potency while reducing toxic side effects. Here, we discuss these research advances, as well as the opportunities and challenges for integrating delivery technologies into cancer immunotherapy, and we critically analyse the outlook for these emerging areas. The rapid progress in cancer immuno therapy has highlighted the need for new delivery technologies. In this article, Langer, Mitchell and colleagues discuss how recent developments in drug delivery could enable new cancer immunotherapies and improve on existing ones, and examine the current delivery obstacles.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/08f736fcedc4c19c9cb3206a30fb77c5e5500f7b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Shugang Qin
2. Min Wu
3. Wen Xiao
4. Qian Zheng
5. Yajun Wang
6. Na Fan
7. T. Gong
8. Ke-Ke Chen

Citations in the corpus

• mRNA-based therapeutics: powerful and versatile tools to combat diseases (2022, background): “Immunotherapy has been an evolving and promising cancer treatment by stimulating the immune system, including immune checkpoint blockade (ICB), chimeric antigen receptor T cells (CAR-T cells), and vaccines.(356) Unlike ICB releasing immunosuppression and CAR-T cells directly killing tumor cells, a c”
• Nanomedicine in cancer therapy (2023, background): “Tumor-targeted drug delivery systems that can specifically accumulate in tumor tissues, selectively recognize and enter tumor cells, and accurately reach subcellular sites of action have long been pursued.(3,4) The past three decades have witnessed a great expansion of research in the field of cance”